PEPTIDE

Abaloparatide (PTHrP analog, Tymlos)

PTHrP analog with selective PTH1R RG conformation binding; faster anabolic effect with reduced hypercalcemia vs. teriparatide.

BIOGATE · AMBER | POSTERIOR 40.8% | MW 3961.0 | 34AA

SEQUENCE

AVSEHQLLHDKGKSIQDLRRRELLEKLLAKLHTA

Modifications: PTHrP-related synthetic 34-residue analog

PDA-V1 chain of custody

Outer hash

bff9cdf3bef9cc60c1f9d119c0f9cf86c3f9d43fc2f9d2acc5f9d76

Merkle root

262-d08c4272d0a57282d0bea292d0d7d222d0278232d040b242d059e252d0731

Inputs

63570773625705-e065570a996457090667570dbf66570c2c695710e568570f52

TEE attestation

e6046ea6e7047039e4046b80e5046d13ea0474f2eb047685e80471cce904735f

Living Outcome Oracle

± =13.9 ² =20.1 **P(success) = 40.8%** 95% CI [28.8%, 52.8%]

Seven-rule export gate

7 / 7 rules satisfied · audience: researcher · Full attestation set, raw posteriors, all hashes

- Grade A or B citation present on the core claim
- BioGate verdict is GREEN or AMBER (RED/BLACK refused)
- Jurisdiction permits the audience-appropriate use
- RWE summary attached when claim depends on outcome data
- Prediction-outcome pairs disclosed when posterior cited
- No human-use claim beyond cited indications
- COA registry lookup available for any synthesis claim

Citations

GRADE A 2016 · JAMA

Effect of Abaloparatide vs Placebo on New Vertebral Fractures (ACTIVE)

Miller PD et al.

PMID 27532316